{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:52:37Z","timestamp":1791381157036,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07975-3","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:59:43Z","timestamp":1791334783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Use of Ivabradine in Contemporary HFrEF: From Heart Rate Reduction to Physiological Optimization"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-7637","authenticated-orcid":false,"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"4","key":"7975_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-018-9696-x","volume":"23","author":"A Bielecka-Dabrowa","year":"2018","unstructured":"Bielecka-Dabrowa A, von Haehling S, Rysz J, Banach M. Novel drugs for heart rate control in heart failure. Heart Fail Rev. 2018;23(4):517\u201325.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"7975_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10741-018-9704-1","volume":"23","author":"D Grande","year":"2018","unstructured":"Grande D, Iacoviello M, Aspromonte N. The effects of heart rate control in chronic heart failure with reduced ejection fraction. Heart Fail Rev. 2018;23(4):527\u201335.","journal-title":"Heart Fail Rev"},{"issue":"9744","key":"7975_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators S. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875\u201385.","journal-title":"Lancet"},{"issue":"10","key":"7975_CR4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Momomura SI, Yamashina A, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Yano M, Yamamoto K, Ako J, Inomata T, Sakata Y, Tanaka T, Kawasaki Y, Investigators JSS. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure\u3000- J-SHIFT Study. Circ J. 2019;83(10):2049\u201360.","journal-title":"Circ J"},{"issue":"15","key":"7975_CR5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","volume":"83","author":"TM Maddox","year":"2024","unstructured":"Maddox TM, Januzzi JL Jr., Allen LA, Breathett K, Brouse S, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444\u201388.","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"7975_CR6","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, Group ESCSD. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"8","key":"7975_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cardfail.2025.02.014","volume":"31","author":"T Kitai","year":"2025","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, Yaku H, Akiyama E, Ando M, Izumi C, Ide T, Iwasaki YK, Ohno Y, Okumura T, Ozasa N, Kaji S, Kashimura T, Kitaoka H, Kinugasa Y, Kinugawa S, Toda K, Nagai T, Nakamura M, Hikoso S, Minamisawa M, Wakasa S, Anchi Y, Oishi S, Okada A, Obokata M, Kagiyama N, Kato NP, Kohno T, Sato T, Shiraishi Y, Tamaki Y, Tamura Y, Nagao K, Nagatomo Y, Nakamura N, Nochioka K, Nomura A, Nomura S, Horiuchi Y, Mizuno A, Murai R, Inomata T, Kuwahara K, Sakata Y, Tsutsui H, Kinugawa K. Japanese Circulation S, the Japanese Heart Failure Society Joint Working G. JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure. J Card Fail. 2025;31(8):1164\u2013322.","journal-title":"J Card Fail"},{"issue":"10","key":"7975_CR8","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.902","volume":"19","author":"A Nikolovska Vukadinovic","year":"2017","unstructured":"Nikolovska Vukadinovic A, Vukadinovic D, Borer J, Cowie M, Komajda M, Lainscak M, Swedberg K, Bohm M. Heart rate and its reduction in chronic heart failure and beyond. Eur J Heart Fail. 2017;19(10):1230\u201341.","journal-title":"Eur J Heart Fail"},{"issue":"9744","key":"7975_CR9","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"M Bohm","year":"2010","unstructured":"Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators S. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886\u201394.","journal-title":"Lancet"},{"issue":"6","key":"7975_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ejheart.2008.04.005","volume":"10","author":"GM De Ferrari","year":"2008","unstructured":"De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, Schwartz PJ, Tavazzi L. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10(6):550\u20135.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"7975_CR11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","volume":"132","author":"N Pal","year":"2015","unstructured":"Pal N, Sivaswamy N, Mahmod M, Yavari A, Rudd A, Singh S, Dawson DK, Francis JM, Dwight JS, Watkins H, Neubauer S, Frenneaux M, Ashrafian H. Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction. Circulation. 2015;132(18):1719\u201325.","journal-title":"Circulation"},{"issue":"5","key":"7975_CR12","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/ehf2.12814","volume":"7","author":"T Izumida","year":"2020","unstructured":"Izumida T, Imamura T, Nakamura M, Fukuda N, Kinugawa K. How to consider target heart rate in patients with systolic heart failure. ESC Heart Fail. 2020;7(5):3231\u20134.","journal-title":"ESC Heart Fail"},{"key":"7975_CR13","doi-asserted-by":"crossref","unstructured":"Yumita Y, Nagatomo Y, Takei M, Saji M, Goda A, Kohno T, Nakano S, Nishihata Y, Ikegami Y, Shiraishi Y, Kohsaka S, Adachi T, Yoshikawa T. Personalized target heart rate for patients with heart failure and reduced ejection fraction. J Pers Med. 2022;12(1):50.","DOI":"10.3390\/jpm12010050"},{"issue":"3","key":"7975_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","volume":"106","author":"D DiFrancesco","year":"2010","unstructured":"DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106(3):434\u201346.","journal-title":"Circ Res"},{"issue":"14","key":"7975_CR15","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","volume":"70","author":"JS Koruth","year":"2017","unstructured":"Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017;70(14):1777\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"7975_CR16","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.hrthm.2025.02.030","volume":"22","author":"JS Copier","year":"2025","unstructured":"Copier JS, Verkerk AO, Lodder EM. HCN4 in the atrioventricular node. Heart Rhythm. 2025;22(9):2160\u201373.","journal-title":"Heart Rhythm"},{"key":"7975_CR17","doi-asserted-by":"crossref","unstructured":"Yamamoto R, Kataoka N, Imamura T, Izumida T, Kinugawa K. PR Interval as a novel therapeutic target of ivabradine therapy-prognostic impact of ivabradine-induced PR prolongation in heart failure patients. J Clin Med. 2024;13(2):510.","DOI":"10.3390\/jcm13020510"},{"issue":"6","key":"7975_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.hrthm.2023.02.012","volume":"20","author":"A Fontenla","year":"2023","unstructured":"Fontenla A, Tamargo J, Salgado R, Lopez-Gil M, Mejia E, Matia R, Toquero J, Montilla I, Rajjoub EA, Garcia-Fernandez FJ, Miracle A, Rey JR, Bueno H. Investigators B-AS. Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial. Heart Rhythm. 2023;20(6):822\u201330.","journal-title":"Heart Rhythm"},{"issue":"22","key":"7975_CR19","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I, Investigators S. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"7975_CR20","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","volume":"15","author":"L Tavazzi","year":"2013","unstructured":"Tavazzi L, Swedberg K, Komajda M, Bohm M, Borer JS, Lainscak M, Ford I, Investigators S. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013;15(11):1296\u2013303.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"7975_CR21","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/ehf2.14455","volume":"10","author":"A Abdin","year":"2023","unstructured":"Abdin A, Komajda M, Borer JS, Ford I, Tavazzi L, Batailler C, Swedberg K, Rosano GMC, Mahfoud F, Bohm M, Investigators S. Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial). ESC Heart Fail. 2023;10(5):2895\u2013902.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"7975_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","volume":"102","author":"M Bohm","year":"2013","unstructured":"Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, Reil JC, Swedberg K, Tavazzi L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102(1):11\u201322.","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"7975_CR23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.hlc.2023.09.005","volume":"33","author":"Y Waranugraha","year":"2024","unstructured":"Waranugraha Y, Rizal A, Tjahjono CT, Vilado IY, David NI, Abudan F, Setyaningrum DA. A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients. Heart Lung Circ. 2024;33(7):962\u201374.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"7975_CR24","first-page":"e77346","volume":"17","author":"A Maharaj","year":"2025","unstructured":"Maharaj A, Maturasingh MB, Khangembam A, Bidhesi SN, Rai S, Garness KA, Khadoo N, Tutwala N, Khan NA, Ramsarran JJ, Bhandari A, Rajbhandari P, Htet KL, Husain MM, Bhagwandeen SN, Rattan K. Effect of Ivabradine on Heart Failure: A 2024 Meta-Analysis. Cureus. 2025;17(1):e77346.","journal-title":"Cureus"},{"issue":"36","key":"7975_CR25","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"13","key":"7975_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jacc.2024.06.002","volume":"84","author":"C Writing","year":"2024","unstructured":"Writing C, Hollenberg SM, Stevenson LW, Ahmad T, Bozkurt B, Butler J, Davis LL, Drazner MH, Kirkpatrick JN, Morris AA, Page RL 2nd, Siddiqi HK, Storrow AB, Teerlink JR. 2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;84(13):1241\u201367.","journal-title":"J Am Coll Cardiol"},{"key":"7975_CR27","doi-asserted-by":"crossref","unstructured":"Imamura T. Clinical implications of ivabradine in the contemporary era. med (Kaunas). 2024;60(2):303.","DOI":"10.3390\/medicina60020303"},{"issue":"24","key":"7975_CR28","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.2169\/internalmedicine.7343-21","volume":"60","author":"M Hori","year":"2021","unstructured":"Hori M, Imamura T, Narang N, Kinugawa K. Implications of Doppler Echocardiography-guided Heart Rate Modulation Using Ivabradine. Intern Med. 2021;60(24):3873\u20137.","journal-title":"Intern Med"},{"issue":"1","key":"7975_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1536\/ihj.21-366","volume":"63","author":"T Imamura","year":"2022","unstructured":"Imamura T, Hori M, Narang N, Besser S, Kinugawa K. Prognostic Implications of Mitral Valve Inflow Pattern Overlap during Ivabradine Therapy. Int Heart J. 2022;63(1):43\u20138.","journal-title":"Int Heart J"},{"issue":"1","key":"7975_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00380-022-02127-7","volume":"38","author":"T Izumida","year":"2023","unstructured":"Izumida T, Imamura T, Kinugawa K. Efficacy of Doppler echocardiography-guided ivabradine therapy. Heart Vessels. 2023;38(1):49\u201355.","journal-title":"Heart Vessels"},{"issue":"25","key":"7975_CR31","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1161\/CIRCULATIONAHA.110.992552","volume":"122","author":"KA Ellenbogen","year":"2010","unstructured":"Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S, Waggoner AD, Lemke B, Singh JP, Spinale FG, Van Eyk JE, Whitehill J, Weiner S, Bedi M, Rapkin J, Stein KM. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122(25):2660\u20138.","journal-title":"Circulation"},{"issue":"4","key":"7975_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/FJC.0000000000001209","volume":"79","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wang W, Li H, Zhang A, Han Y, Wang J, Hou Y. Ivabradine and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022;79(4):549\u201357.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"7975_CR33","doi-asserted-by":"publisher","first-page":"e70012","DOI":"10.1111\/anec.70012","volume":"29","author":"J Han","year":"2024","unstructured":"Han J, Wang Q, Jiang L, Yin X. Efficacy and Safety of Ivabradine for Patients With Acute Heart Failure: Meta-Analysis of Randomized Controlled Trials. Ann Noninvasive Electrocardiol. 2024;29(6):e70012.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"8","key":"7975_CR34","doi-asserted-by":"publisher","first-page":"102604","DOI":"10.1016\/j.cpcardiol.2024.102604","volume":"49","author":"S Ashraf","year":"2024","unstructured":"Ashraf S, Khalaf AKS, Fatima L, Hashim HT, Irfan H, Ashfaq H, Khan MA, Zahid A, Akram U, Goyal A. Evaluating the role of ivabradine in acute decompensated heart failure: A systematic review and meta-analysis. Curr Probl Cardiol. 2024;49(8):102604.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"7975_CR35","doi-asserted-by":"publisher","first-page":"e24206","DOI":"10.1002\/clc.24206","volume":"47","author":"TH Tsai","year":"2024","unstructured":"Tsai TH, Tsai ML, Chen DY, Lin Y, Peng JR, Yang NI, Hung MJ, Chen TH. Evaluating the applicability of ivabradine in acute heart failure. Clin Cardiol. 2024;47(1):e24206.","journal-title":"Clin Cardiol"},{"issue":"4","key":"7975_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1536\/ihj.18-559","volume":"60","author":"H Pei","year":"2019","unstructured":"Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, Zhao Z. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure. Int Heart J. 2019;60(4):899\u2013909.","journal-title":"Int Heart J"},{"issue":"2","key":"7975_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","volume":"151","author":"M Volterrani","year":"2011","unstructured":"Volterrani M, Cice G, Caminiti G, Vitale C, D\u2019Isa S, Perrone Filardi P, Acquistapace F, Marazzi G, Fini M, Rosano GM. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218\u201324.","journal-title":"Int J Cardiol"},{"issue":"1","key":"7975_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10741-012-9332-0","volume":"18","author":"LP Cahalin","year":"2013","unstructured":"Cahalin LP, Chase P, Arena R, Myers J, Bensimhon D, Peberdy MA, Ashley E, West E, Forman DE, Pinkstaff S, Lavie CJ, Guazzi M. A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev. 2013;18(1):79\u201394.","journal-title":"Heart Fail Rev"},{"issue":"7","key":"7975_CR39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jchf.2018.03.017","volume":"6","author":"O Ciani","year":"2018","unstructured":"Ciani O, Piepoli M, Smart N, Uddin J, Walker S, Warren FC, Zwisler AD, Davos CH, Taylor RS. Validation of Exercise Capacity as a Surrogate Endpoint in Exercise-Based Rehabilitation for Heart Failure: A Meta-Analysis of Randomized Controlled Trials. JACC Heart Fail. 2018;6(7):596\u2013604.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"7975_CR40","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, Bohm M, prEserve DFI. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19(11):1495\u2013503.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"7975_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1536\/ihj.20-788","volume":"62","author":"T Izumida","year":"2021","unstructured":"Izumida T, Imamura T, Fukui T, Koi T, Ueno Y, Hori M, Nakagaito M, Tanaka S, Kataoka N, Ushijima R, Nakamura M, Sobajima M, Fukuda N, Ueno H, Kinugawa K. How to Estimate the Optimal Heart Rate in Patients with Heart Failure with Preserved Ejection Fraction. Int Heart J. 2021;62(4):816\u201320.","journal-title":"Int Heart J"},{"issue":"2","key":"7975_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14779072.2026.2618040","volume":"24","author":"CS Kow","year":"2026","unstructured":"Kow CS, Zaihan AF, Hasan SS, Thiruchelvam K. Ivabradine in acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Cardiovasc Ther. 2026;24(2):123\u201335.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"12","key":"7975_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, Investigators S. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"7975_CR44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1536\/ihj.24-027","volume":"65","author":"T Izumida","year":"2024","unstructured":"Izumida T, Imamura T, Onoda H, Tanaka S, Ushijima R, Ueno H, Kinugawa K. Effect of Optimal Heart Rate on Left Ventricular Remodeling in Patients with Systolic Heart Failure Following Acute Coronary Syndrome. Int Heart J. 2024;65(5):833\u201340.","journal-title":"Int Heart J"},{"issue":"4","key":"7975_CR45","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/jocs.15394","volume":"36","author":"T Imamura","year":"2021","unstructured":"Imamura T, Tanaka S, Ushijima R, Sobajima M, Fukuda N, Ueno H, Besser S, Kinugawa K. The implication of optimal heart rate in patients with systolic dysfunction following TAVR. J Card Surg. 2021;36(4):1328\u201333.","journal-title":"J Card Surg"},{"issue":"1","key":"7975_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1536\/ihj.21-468","volume":"63","author":"T Imamura","year":"2022","unstructured":"Imamura T, Kinugawa K, Narang N, Nishida H, Pinney S, Jeevanandam V, Ota T. Implications of Heart Rate in Patients with Left Ventricular Assist Devices. Int Heart J. 2022;63(1):56\u201361.","journal-title":"Int Heart J"},{"key":"7975_CR47","doi-asserted-by":"crossref","unstructured":"Izumida T, Imamura T, Nakamura M, Kinugawa K. Optimal heart rate and prognosis in patients with cardiac amyloidosis. J Cardiovasc Dev Dis. 2021;8(12):182.","DOI":"10.3390\/jcdd8120182"},{"issue":"4","key":"7975_CR48","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1536\/ihj.20-751","volume":"62","author":"T Imamura","year":"2021","unstructured":"Imamura T, Narang N, Besser S, Kinugawa K. Chronotropic Assessment in Patients with Constrictive Pericarditis. Int Heart J. 2021;62(4):811\u20135.","journal-title":"Int Heart J"},{"issue":"4","key":"7975_CR49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000380812","volume":"131","author":"EA Bocchi","year":"2015","unstructured":"Bocchi EA, Bohm M, Borer JS, Ford I, Komajda M, Swedberg K, Tavazzi L, investigators S. Effect of Combining Ivabradine and beta-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. Cardiology. 2015;131(4):218\u201324.","journal-title":"Cardiology"},{"issue":"11","key":"7975_CR50","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1007\/s00380-021-01864-5","volume":"36","author":"T Izumida","year":"2021","unstructured":"Izumida T, Imamura T, Ueno Y, Tanaka S, Kataoka N, Nakamura M, Kinugawa K. Impact of optimal heart rate on left ventricular reverse remodeling and functional improvement in patients with systolic heart failure. Heart Vessels. 2021;36(11):1688\u201393.","journal-title":"Heart Vessels"},{"issue":"2","key":"7975_CR51","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.hrthm.2022.10.018","volume":"20","author":"A D\u2019Onofrio","year":"2023","unstructured":"D\u2019Onofrio A, Marini M, Rovaris G, Zanotto G, Calvi V, Iacopino S, Biffi M, Solimene F, Della Bella P, Caravati F, Pisano EC, Amellone C, D\u2019Alterio G, Pedretti S, Santobuono VE, Russo AD, Nicolis D, De Salvia A, Baroni M, Quartieri F, Manzo M, Rapacciuolo A, Saporito D, Maines M, Marras E, Bontempi L, Morani G, Giacopelli D, Gargaro A, Giammaria M. Prognostic significance of remotely monitored nocturnal heart rate in heart failure patients with reduced ejection fraction. Heart Rhythm. 2023;20(2):233\u201340.","journal-title":"Heart Rhythm"},{"issue":"3","key":"7975_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/heartjnl-2015-308428","volume":"102","author":"RM Cubbon","year":"2016","unstructured":"Cubbon RM, Ruff N, Groves D, Eleuteri A, Denby C, Kearney L, Ali N, Walker AM, Jamil H, Gierula J, Gale CP, Batin PD, Nolan J, Shah AM, Fox KA, Sapsford RJ, Witte KK, Kearney MT. Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure. Heart. 2016;102(3):223\u20139.","journal-title":"Heart"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07975-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:02:18Z","timestamp":1791378138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07975-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":52,"alternative-id":["7975"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07975-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"24 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}